Gardette Forte (Budesonide/Formoterol)
Inhalation powder for asthma and COPD maintenance therapy
Gardette forte is a combination inhaler containing budesonide (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist). It is prescribed for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Budesonide reduces airway inflammation while formoterol relaxes bronchial smooth muscle, providing sustained bronchodilation for at least 12 hours. This medicine requires a prescription and must not be used as a rescue inhaler for sudden breathing problems.
Quick Facts
Key Takeaways
- Gardette forte combines an anti-inflammatory corticosteroid (budesonide) with a long-acting bronchodilator (formoterol) in a single inhaler for convenient twice-daily dosing.
- It is approved for maintenance treatment of asthma and severe COPD with a history of recurrent exacerbations — it is not for acute relief of breathing difficulties.
- Always rinse your mouth with water after each inhalation to reduce the risk of oral thrush (candidiasis), the most common side effect.
- Tell your doctor about all other medicines you take, especially beta-blockers, CYP3A4 inhibitors (such as ketoconazole), and QT-prolonging drugs.
- Do not stop using Gardette forte suddenly without medical advice, even if you feel better — gradual dose reduction may be necessary.
What Is Gardette Forte and What Is It Used For?
Gardette forte belongs to the pharmacotherapeutic group of adrenergics in combination with corticosteroids (ATC code R03AK07). It is a dry powder inhaler that delivers a fixed-dose combination of two active substances with complementary mechanisms of action. The combination addresses both the underlying inflammation and the bronchoconstriction that characterize obstructive airway diseases.
Budesonide is a potent glucocorticoid with a high local anti-inflammatory effect in the lungs. It works by inhibiting the release of inflammatory mediators and cytokines, reducing eosinophilic infiltration, mucus hypersecretion, and airway hyperresponsiveness. Budesonide has a relatively rapid onset of anti-inflammatory effect, with some improvement in lung function noticeable within hours, although maximum benefit may take several weeks of regular use.
Formoterol fumarate dihydrate is a selective long-acting beta-2 adrenoceptor agonist (LABA) that relaxes bronchial smooth muscle by stimulating beta-2 receptors. Unlike some other LABAs, formoterol has a rapid onset of action (within 1–3 minutes after inhalation), while maintaining a duration of action of at least 12 hours. This dual property makes it particularly well-suited for regular twice-daily dosing.
Approved Indications
Asthma: Gardette forte is indicated for the regular treatment of asthma where the use of a combination product (inhaled corticosteroid and long-acting beta-2 agonist) is appropriate. This includes patients not adequately controlled with inhaled corticosteroids and as-needed short-acting beta-2 agonists, as well as patients already adequately controlled on both an inhaled corticosteroid and a long-acting beta-2 agonist. According to GINA (Global Initiative for Asthma) 2024 guidelines, medium-to-high dose ICS/LABA combinations represent Step 4–5 therapy for patients with moderate-to-severe persistent asthma.
Chronic Obstructive Pulmonary Disease (COPD): Gardette forte is indicated for the symptomatic treatment of patients with severe COPD (FEV1 <50% of predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2024 report recommends ICS/LABA combinations for patients in Group E with elevated blood eosinophils (≥300 cells/μL) or those with a history of frequent and/or severe exacerbations.
Gardette forte is a generic equivalent of budesonide/formoterol combination inhalers and contains the same well-established active ingredients. It is manufactured to meet stringent European regulatory standards and has been demonstrated to be bioequivalent to the originator product. This ensures comparable clinical efficacy and safety profiles.
What Should You Know Before Taking Gardette Forte?
Contraindications
You must not use Gardette forte if you have a known hypersensitivity to budesonide, formoterol fumarate dihydrate, or inhaled lactose (which may contain small amounts of milk proteins). Patients with a rare hereditary condition of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not use this product due to the lactose monohydrate excipient.
Gardette forte is not intended for the relief of acute asthma episodes or acute bronchospasm. A separate short-acting inhaled beta-2 agonist (such as salbutamol or terbutaline) must be available for rescue use. If you find that you need your rescue inhaler more often than usual, this may indicate worsening of your underlying condition, and you should seek medical advice promptly.
Warnings and Precautions
Special care is needed if you have any of the following conditions, as these may require closer monitoring or dose adjustment:
- Cardiovascular conditions: Coronary artery disease, cardiac arrhythmias (particularly third-degree atrioventricular block), severe heart failure, idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, or severe hypertension.
- QT interval prolongation: Formoterol may induce prolongation of the QTc interval. Patients with congenital or drug-induced long QT syndrome require careful monitoring.
- Endocrine disorders: Thyrotoxicosis, diabetes mellitus (inhaled corticosteroids may increase blood glucose levels), uncontrolled hypokalemia, and pheochromocytoma.
- Infections: Active or quiescent pulmonary tuberculosis, fungal or viral infections of the airways.
- Osteoporosis: Long-term use of high-dose inhaled corticosteroids may reduce bone mineral density.
- Adrenal function: Prolonged treatment with high doses of inhaled corticosteroids may lead to adrenal suppression and adrenal crisis, particularly during periods of stress or surgery.
Do not suddenly stop using Gardette forte without consulting your doctor. Abrupt discontinuation of inhaled corticosteroids may lead to worsening of asthma or COPD symptoms and potentially trigger an adrenal crisis if systemic corticosteroid effects have developed. Your doctor will guide a gradual dose reduction when appropriate.
Patients should be advised to rinse the mouth with water after each inhalation to minimize the risk of oropharyngeal candidiasis (thrush) and dysphonia (hoarseness). If oral thrush develops, treatment with a topical antifungal agent may be necessary while continuing Gardette forte therapy.
Pregnancy and Breastfeeding
Pregnancy: Gardette forte should only be used during pregnancy when the expected benefit to the mother justifies the potential risk to the fetus. Budesonide is the most extensively studied inhaled corticosteroid in pregnancy, with data from large epidemiological studies showing no increased risk of congenital malformations. However, poorly controlled asthma itself carries significant risks to both the mother and fetus, including pre-eclampsia, premature birth, and low birth weight. The lowest effective dose of budesonide that maintains adequate asthma control should be used. Data on formoterol in pregnancy are limited; animal reproduction studies at very high doses have shown adverse effects, but these are not considered clinically relevant at therapeutic doses.
Breastfeeding: Budesonide is excreted in breast milk in small amounts. At therapeutic inhaled doses, the amount reaching the infant is expected to be negligible, and effects on the breastfed infant are unlikely. Excretion of formoterol into human breast milk is unknown, but it has been detected in the milk of lactating rats. A clinical decision must weigh the benefit of breastfeeding for the child and the benefit of continued therapy for the mother. Generally, inhaled budesonide/formoterol at recommended doses is considered compatible with breastfeeding.
Children and Adolescents
Gardette forte (320/9 mcg strength) is suitable for adolescents aged 12 years and older. It is not recommended for children under 12 years; lower-strength budesonide/formoterol formulations should be used instead. Regular monitoring of growth in children and adolescents receiving prolonged inhaled corticosteroid therapy is recommended, as high-dose inhaled corticosteroids may cause a small, transient reduction in growth velocity (approximately 1 cm in the first year of treatment). This effect is generally not considered clinically significant over the long term.
How Does Gardette Forte Interact with Other Drugs?
Drug interactions with Gardette forte may affect either or both of its active ingredients. Budesonide is metabolized primarily by the liver enzyme CYP3A4, making it susceptible to interactions with drugs that inhibit or induce this enzyme. Formoterol, as a beta-2 adrenergic agonist, can interact with drugs affecting the sympathetic nervous system, cardiac conduction, or potassium balance.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Ketoconazole, Itraconazole (CYP3A4 inhibitors) | May increase systemic budesonide exposure by up to 6-fold, increasing risk of adrenal suppression and other systemic corticosteroid effects | Avoid prolonged concomitant use. If necessary, extend the time interval and consider dose reduction of budesonide. |
| Ritonavir, Nelfinavir, Cobicistat (HIV protease inhibitors) | Potent CYP3A4 inhibition; markedly increased budesonide plasma levels with risk of Cushing syndrome and adrenal suppression | Combination should be avoided. If unavoidable, careful monitoring of systemic corticosteroid effects is essential. |
| Non-selective beta-blockers (propranolol, carvedilol, sotalol) | May reduce or completely block the bronchodilatory effect of formoterol, potentially worsening bronchospasm | Non-selective beta-blockers (including eye drops) are contraindicated. Cardioselective beta-blockers may be used with caution. |
| QT-prolonging drugs (quinidine, disopyramide, amiodarone, erythromycin, certain antipsychotics) | Additive QTc prolongation; increased risk of ventricular arrhythmias including torsades de pointes | Use with caution. ECG monitoring may be warranted. Discuss risk-benefit with prescriber. |
| MAO inhibitors, Tricyclic antidepressants | Potentiation of formoterol's cardiovascular effects (tachycardia, hypertension, arrhythmias) | Use with extreme caution. Avoid if possible during and within 2 weeks after MAO inhibitor treatment. |
Minor Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Theophylline, Aminophylline | Additive hypokalemia risk; theophylline may also enhance the bronchodilator effect | Monitor serum potassium levels, especially during exacerbations. |
| Diuretics (furosemide, hydrochlorothiazide) | Additive potassium-lowering effect with formoterol | Monitor potassium levels periodically. Supplement if needed. |
| Other sympathomimetics (oral salbutamol, pseudoephedrine) | Potentiated beta-2 agonist effects; increased risk of tachycardia, tremor, and hypokalemia | Use concurrently with caution. Short-acting rescue inhalers are acceptable. |
| Systemic corticosteroids (prednisolone, dexamethasone) | Additive corticosteroid effects; increased risk of adrenal suppression and other systemic effects | Use the lowest effective dose. Taper systemic steroids gradually when transitioning to inhaled therapy. |
Although grapefruit juice is a mild CYP3A4 inhibitor, the interaction with inhaled budesonide is not considered clinically significant at normal dietary intake. However, excessive or regular consumption of large quantities of grapefruit juice should be mentioned to your doctor.
What Is the Correct Dosage of Gardette Forte?
The dosage of Gardette forte should be individualized based on the severity of the disease and the patient's response to treatment. The lowest dose that maintains effective symptom control should always be used. Once asthma or COPD is well-controlled, titration to the lowest effective dose should be attempted. Patients should not exceed the maximum recommended dose.
Adults (18 Years and Older)
Asthma — Maintenance Therapy
Standard dose: 1 inhalation twice daily (morning and evening).
Higher dose: 2 inhalations twice daily, for patients requiring a higher dose to achieve adequate control.
Maximum: 4 inhalations per day (2 inhalations twice daily).
When good asthma control is achieved and maintained, gradually reduce to the lowest effective dose, which may include stepping down to a lower-strength budesonide/formoterol formulation or an inhaled corticosteroid alone.
COPD — Maintenance Therapy
Standard dose: 1 inhalation twice daily (morning and evening).
Maximum: 2 inhalations twice daily (4 inhalations per day).
Adolescents (12–17 Years)
Asthma — Maintenance Therapy
Standard dose: 1 inhalation twice daily.
Maximum: 2 inhalations twice daily.
Adolescents should be reviewed regularly by their prescriber. Once asthma is controlled, the dose should be titrated to the lowest effective level.
Children (Under 12 Years)
Not Recommended
Gardette forte 320 mcg/9 mcg is not recommended for children under 12 years. Lower-strength budesonide/formoterol formulations (e.g., 80/4.5 mcg or 160/4.5 mcg) are available for paediatric patients requiring combination ICS/LABA therapy.
Elderly (65 Years and Older)
No Dose Adjustment Required
No specific dose adjustment is needed for elderly patients. Standard adult dosing applies. However, elderly patients may be more susceptible to systemic corticosteroid effects and cardiovascular effects of beta-2 agonists, so monitoring should be individualized.
How to Use the Inhaler
Proper inhaler technique is essential for effective drug delivery to the lungs. Poor technique is one of the most common reasons for inadequate asthma or COPD control. Follow these steps:
- Prepare the inhaler: Open the inhaler and load a dose according to the device instructions. Do not shake the inhaler — this is a dry powder device.
- Breathe out: Exhale fully away from the mouthpiece. Do not breathe out into the device, as moisture can affect the powder.
- Inhale deeply: Place your lips firmly around the mouthpiece and inhale deeply and forcefully through your mouth. The powder is delivered by your breath — a forceful inhalation is needed to draw the medicine into your lungs.
- Hold your breath: Remove the inhaler from your mouth and hold your breath for about 10 seconds, or as long as comfortably possible.
- Rinse your mouth: Rinse your mouth with water and spit it out after each dose to reduce the risk of oral thrush and hoarseness.
- Close the inhaler: Replace the cap and store in a dry place.
Missed Dose
If you forget a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a missed one. Maintaining a regular schedule (e.g., morning and evening at the same times each day) helps ensure consistent drug levels and optimal disease control.
Overdose
An acute overdose of formoterol may cause tremor, headache, palpitations, tachycardia, nausea, and hypokalemia. In severe cases, metabolic acidosis, hyperglycemia, and cardiac arrhythmias may occur. Treatment is supportive and symptomatic. Cardioselective beta-blockers may be considered with extreme caution, as they may provoke bronchospasm. Serum potassium should be monitored.
Chronic overdose of budesonide may result in adrenal suppression and other systemic glucocorticoid effects, including Cushing syndrome, reduced bone mineral density, cataracts, and growth retardation in children. There is no specific antidote for budesonide overdose; management is supportive with gradual dose reduction under medical supervision.
If overdose is suspected, contact a poison control center or seek emergency medical attention immediately.
What Are the Side Effects of Gardette Forte?
Like all medicines, Gardette forte can cause side effects, although not everybody gets them. Most side effects are mild and tend to reduce with continued treatment. The frequency of side effects is classified according to the following convention:
Common Side Effects
Affects 1 to 10 in every 100 patients
- Oral candidiasis (thrush) — white patches in the mouth; prevented by mouth rinsing
- Headache — usually mild and transient
- Tremor — fine trembling of the hands, typically dose-related
- Palpitations — awareness of heartbeat; usually benign
- Throat irritation — mild soreness or tickling in the throat
- Cough — may occur immediately after inhalation
- Hoarseness (dysphonia) — voice changes; reduced by mouth rinsing
Uncommon Side Effects
Affects 1 to 10 in every 1,000 patients
- Tachycardia — rapid heart rate
- Nausea
- Muscle cramps
- Dizziness
- Sleep disturbances — insomnia or restlessness
- Bruising — easy skin bruising
- Nervousness and agitation
Rare Side Effects
Affects fewer than 1 in 1,000 patients
- Paradoxical bronchospasm — worsening of breathing immediately after inhalation; discontinue and seek medical help
- Allergic reactions — rash, urticaria (hives), angioedema, anaphylaxis
- Hypokalemia — low potassium levels, potentially causing muscle weakness and cardiac arrhythmias
- Hyperglycemia — elevated blood sugar levels
- Behavioural disturbances — especially in children; restlessness, hyperactivity, depression, aggression
- Adrenal suppression — with prolonged high-dose use
- Growth retardation in children — small transient reduction in growth velocity
- Cataracts and glaucoma — with long-term high-dose use
- Cardiac arrhythmias — atrial fibrillation, supraventricular tachycardia, extrasystoles
You experience sudden worsening of breathlessness after inhalation (paradoxical bronchospasm), swelling of the face, lips, tongue or throat (angioedema), severe skin rash or hives, chest pain, irregular heartbeat, or signs of a serious allergic reaction. These are rare but potentially serious events requiring emergency care.
Long-term use of high-dose inhaled corticosteroids may rarely cause systemic effects including osteoporosis, adrenal suppression, growth retardation in children and adolescents, reduced bone mineral density, cataracts, and glaucoma. The risk of these systemic effects is substantially lower with inhaled corticosteroids compared to oral corticosteroids. The benefits of well-controlled asthma or COPD generally outweigh the risks of potential systemic effects.
Inhaled corticosteroids may also be associated with an increased risk of pneumonia in COPD patients. Signs of pneumonia include fever, increased sputum production, change in sputum color, increased cough, and worsening breathlessness. If you develop these symptoms, contact your doctor, but do not stop using your inhaler without medical advice.
If you experience any side effect that is bothersome, persistent, or concerning, report it to your doctor or pharmacist. You can also report side effects directly to your national adverse drug reaction reporting system.
How Should You Store Gardette Forte?
Proper storage of Gardette forte is important to ensure the medicine remains effective throughout its shelf life. The dry powder formulation is sensitive to moisture, which can cause clumping of the powder and reduce the delivered dose.
- Temperature: Store below 30°C (86°F). Do not freeze.
- Moisture: Keep the inhaler dry at all times. Do not expose the device to water or high humidity. Do not wash the mouthpiece with water — wipe it with a dry cloth if needed.
- Cap: Always replace the protective cap after each use to protect from moisture and dust.
- Children: Keep out of the sight and reach of children.
- Expiry date: Do not use the medicine after the expiry date printed on the packaging. The expiry date refers to the last day of that month.
- Disposal: Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use to help protect the environment.
If you carry the inhaler with you (e.g., in a bag or pocket), ensure it is protected from extreme temperatures and moisture. Avoid leaving it in a car during hot weather or in a bathroom where humidity levels are high.
What Does Gardette Forte Contain?
Understanding the composition of your medicine helps identify potential allergens and ensures safe use.
Active Ingredients (Per Inhalation)
| Ingredient | Metered Dose | Delivered Dose (approx.) | Role |
|---|---|---|---|
| Budesonide | 320 micrograms | ~256 micrograms | Inhaled corticosteroid (anti-inflammatory) |
| Formoterol fumarate dihydrate | 9 micrograms | ~7.2 micrograms | Long-acting beta-2 agonist (bronchodilator) |
Excipient
The only excipient in Gardette forte is lactose monohydrate, which serves as a carrier for the active substances in the dry powder formulation. Lactose monohydrate may contain small amounts of milk proteins. Patients with severe milk protein allergy (not common lactose intolerance) should discuss this with their doctor, although clinically significant allergic reactions to lactose in inhalers are extremely rare.
The inhaler device itself does not contain any electronic components or propellants. It is a breath-actuated dry powder inhaler, meaning the medicine is delivered as a fine powder that is drawn into the lungs by the patient's own inspiratory effort. No coordination between pressing a canister and inhaling is required, which can be an advantage for patients who find pressurized metered-dose inhalers difficult to use.
Frequently Asked Questions About Gardette Forte
Gardette forte is used for the maintenance treatment of asthma in patients aged 12 years and older who are not adequately controlled with inhaled corticosteroids alone and as-needed short-acting beta-2 agonists, or in patients already well-controlled on both an inhaled corticosteroid and a long-acting beta-2 agonist. It is also used for the symptomatic treatment of severe COPD (FEV1 <50% of predicted) with a history of repeated exacerbations. It is not intended for relief of acute asthma attacks or sudden breathlessness.
No. Gardette forte (320/9 mcg) is generally not recommended as a reliever inhaler. The lower-strength budesonide/formoterol formulations (such as 160/4.5 mcg) may be used as both maintenance and reliever therapy (the MART approach) in asthma, as recommended by GINA guidelines. For acute relief of symptoms when using Gardette forte, a separate short-acting beta-2 agonist such as salbutamol should be kept available at all times.
The most common side effects include oral candidiasis (thrush) appearing as white patches in the mouth, headache, tremor (fine shaking of the hands), palpitations (awareness of your heartbeat), throat irritation, cough after inhalation, and hoarseness. Most of these are mild and can be minimized by rinsing your mouth thoroughly with water after each inhalation and spitting the water out. If side effects are persistent or bothersome, consult your doctor.
Yes, absolutely. Rinsing your mouth with water after each inhalation is strongly recommended and should become a routine part of your inhaler use. This simple step significantly reduces the risk of developing oral candidiasis (thrush) and hoarseness, which are the most common local side effects of inhaled corticosteroids. After rinsing, spit the water out — do not swallow it, as this would increase systemic absorption of any budesonide deposited in the mouth.
Gardette forte should only be used during pregnancy if the expected benefit to the mother justifies the potential risk. However, it is important to note that budesonide is the most extensively studied inhaled corticosteroid in pregnancy, with data from multiple large studies showing no increased risk of birth defects. Poorly controlled asthma carries its own significant risks to both mother and baby, including pre-eclampsia, premature delivery, and low birth weight. Your doctor will help you weigh the benefits and risks to find the safest approach for your situation.
Gardette forte is a generic equivalent of Symbicort forte Turbuhaler. Both products contain the same active ingredients in the same doses: budesonide 320 micrograms and formoterol fumarate dihydrate 9 micrograms per inhalation. They have been demonstrated to be bioequivalent, meaning they deliver the same amount of medicine to the lungs and produce the same clinical effect. The main differences may be in the inhaler device design and appearance, but the therapeutic outcome is the same. Generic medicines must meet the same quality, safety, and efficacy standards as the originator product.
References
This article is based on the following evidence-based medical sources:
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024 Update. Available at: ginasthma.org
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD: 2024 Report. Available at: goldcopd.org
- European Medicines Agency (EMA). Budesonide/Formoterol Summary of Product Characteristics. Available at: ema.europa.eu
- British National Formulary (BNF). Budesonide with formoterol (inhalation). National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- World Health Organization (WHO). Model List of Essential Medicines, 23rd Edition, 2023. Geneva: WHO. Available at: who.int
- Bateman ED, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol. 2010;125(3):600-608. doi:10.1016/j.jaci.2009.11.033
- Pauwels RA, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337(20):1405-1411. doi:10.1056/NEJM199711133372001
- Calverley PMA, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789. doi:10.1056/NEJMoa063070
- Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol. 2003;111(4):736-742. doi:10.1067/mai.2003.1340
- U.S. Food and Drug Administration (FDA). Long-Acting Beta-Agonists (LABAs): New Safety Requirements. FDA Drug Safety Communication. Available at: fda.gov
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians specializing in respiratory medicine, clinical pharmacology, and pulmonology. All content follows the GRADE evidence framework and adheres to international guidelines from GINA, GOLD, EMA, and WHO.
Written by specialists in respiratory medicine with clinical experience in asthma and COPD management. All medical claims are supported by Level 1A evidence from systematic reviews and randomized controlled trials.
Independently reviewed by the iMedic Medical Review Board to ensure clinical accuracy, completeness, and adherence to current evidence-based guidelines. No commercial funding or pharmaceutical sponsorship.
Last medical review: | Next scheduled review: